Journal of Isfahan Medical School

Journal of Isfahan Medical School

Investigating Serum Prolactin Levels in Different Stages of Chronic Kidney Disease

Document Type : Original Article(s)

Authors
Neda Meftah 1
Marziyeh Jamshidi 2
Marjan Mouodi 3
Sara Babazadeh 4
Hemmat Gholinia 5
Narges Mostafaloo 6
1 Associate Professor of Endocrinology & Metabolism, Department of Internal Medicine, School of Medicine, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
2 Resident, Department of Internal Medicine; Student Research Committee; Babol University of Medical Sciences, Babol, Iran
3 Assistant Professor of Endocrinology & Metabolism, Department of Internal Medicine, School of Medicine, Rouhani Hospital, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, Iran
4 Assistant Professor of Pathology, Department of Pathology, School of Medicine, Rouhani Hospital, Shahid Yahya Nezhad hospital, Babol University of Medical Sciences, Babol, Iran
5 Health Research Institute, Babol University of Medical Sciences, Babol, Iran
6 Assistant Professor of Nephrology, Department of Internal Medicine, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
10.48305/jims.v44.i876.1584
Abstract
Background: Chronic kidney disease (CKD) is a growing global concern marked by progressive, irreversible renal function loss. Prolactin, a pituitary hormone, accumulates in renal failure and is linked to various complications. However, data on prolactin changes across all non‑dialysis CKD stages remain scarce. This study aimed to assess serum prolactin levels across different CKD stages and their correlation with renal function indicators.
Methods: This cross‑sectional study enrolled CKD patients attending Babol University of Medical Sciences clinics (2024–2025). After written consent, demographic data were recorded. Fasting morning serum prolactin and creatinine were measured in a single laboratory. Data were analysed using SPSS 26, with p<0.05 considered significant.
Results: Among 70 patients (54.3% male, mean age 64.8 years), most were in stages G3b–G5. Mean creatinine was 3.38 mg/dL. Prolactin levels were significantly higher in advanced stages than in early stages (p<0.001), consistent across both sexes. Prolactin positively correlated with creatinine (r=0.896, p<0.001) and negatively with GFR (r=‑0.925, p<0.001).
Conclusion: Prolactin rises with CKD progression, correlating with creatinine and GFR in both sexes, supporting its role as a relevant marker in CKD. Nevertheless, due to the cross‑sectional design and lack of complete clinical parameters, causal inferences cannot be firmly established.

Highlights

Neda Meftah:Google Scholar

Marjan Mouodi: Google Scholar

Sara Babazadeh: Google Scholar

Hemat Gholinia : Google Scholar

Narges Mostafaloo: Google Scholar

Keywords
Prolactin
Chronic Kidney Disease
Hyperprolactinemia
Glomerular Filtration Rate
Biomarker
Subjects
1.     Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021; 398(10302): 786-802. 
2.     GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 2025; 406(10518): 2461-82. 
3.      Madero M, Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, et al. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline. Ann Intern Med 2025; 178(5): 705-13. 
4.     Evans M, Lewis RD, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther 2022; 39(1): 33-43.
5.     Chasseloup F, Bernard V, Chanson P. Prolactin: structure, receptors, and functions. Rev Endocr Metab Disord 2024; 25(6): 953-66. 
6.     Rojhani E, Rahmati M, Firouzi F, Ziaeefar P, Soudmand SA, Azizi F, et al. Prolactin levels and chronic kidney disease and the subsequent risk of cardiovascular events: A long term population based cohort study. Sci Rep 2025; 15(1): 7198. 
7.     Nakamura RM, Yela DA, Santos AC, Ribas BC, Rosa e Silva PH, Motta BN, et al. Depression, anxiety, sexual function and quality of life in women with hyperprolactinemia. Rev Bras Ginecol Obstet 2025; 47: e-rbgo7. 
8.     Tritos NA, Klibanski A. Prolactin and Its Role in Human Reproduction. In: Strauss JF, Barbieri RL, editors. Yen & Jaffe's Reproductive Endocrinology. 9th ed. Philadelphia: Elsevier; 2024. p. 62-78. 
9.      Iatridi F, Carrero JJ, Cornec-Le Gall E, Kanbay M, Luyckx V, Shroff R, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease in children and adults: a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant 2024; 40(2): 273-85. 
10.  Gamman SE, Hammad FK, Taha WA, Bakheet OH, Ahmad IH. Serum prolactin level in male patients with chronic kidney diseases. Sci J Al-Azhar Med Fac Girls 2021; 5(3): 456-62. 
11.  Elbardisi H, Majzoub A, Daniel C, Al Ali F, Elesnawi M, Khalafalla K, ET AL. Endocrine contribution to the sexual dysfunction in patients with advanced chronic kidney disease and the role of hyperprolactinemia. Andrologia 2021; 53(8): e14135.
12.  Muthina RA, Koppara NK, Kiranmayi V, Vaikkakara S, Vishnubotla S. Gonadal functional status and its correlation with body composition in adult men with

non-diabetic chronic kidney disease non-dialysis-dependent stage. J Clin Sci Res 2024; 13(4): 221-8. 
13.  Huang W, Molitch ME. Prolactin and Other Pituitary Disorders in Kidney Disease. Semin Nephrol 2021; 41(2): 156-67. 
14.  Al-Zuhairi L, Wafaa S, Abdulmajeed A. Evaluation of serum prolactin level in chronic kidney disease in iraqi patients. Biochem Cell Arch 2019; 19: 489-93.
15.  Rusu CC, Moldovan D, Potra A, Tirinescu D, Ticala M, Maslyennikov Y, et al. The Interplay of Prolactin with Inflammatory Nutritional Markers and NT-proBNP in Chronic Kidney Disease. Int J Mol Sci 2025; 26(13): 6347. 
16.  Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic Kidney Disease, and Cardiovascular Risk. Int J Endocrinol 2020; 2020: 9524839. 
17.  Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS. Metabolic effects of prolactin. Front Endocrinol. 2022; 13: 1015520. 
18.  Rasmi Y, Jalali L, Khalid S, Shokati A, Tyagi P, Ozturk A, et al. The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect. Cytokine 2023; 169: 156253. 
19.  Katerenchuk IP, Rustamyan ST, Talash VV, Yarmola TI. Hormonal imbalance in patients with chronic renal failure in the pre-dialysis and dialysis periods (part 1). Int J Endocrinol 2023; 18(1): 65-71. 
20.  Parak A, Daya R, Bulbulia S, Seedat F, Bayat Z. Hyperprolactinaemia in a patient with kidney failure. African Journal of Nephrology. 2020; 23(1): 172-4. 
21.  Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol 2024; 20(7): 473-85. 
22.  Hesaraki M, Behzadmehr R, Goli H, Rafiemanesh H, Doostkami M. Causes of chronic kidney disease in the general population of Iran: A systematic review and meta-analysis. Nephrol Ther 2022; 18(7): 584-90. 
23.  Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in chronic kidney disease: a narrative review. Clin Kidney J 2023; 16(4): 601-11. 
24.   Kishi S, Nagasu H, Kidokoro K, Kashihara N. Oxidative stress and the role of redox signalling in chronic kidney disease. Nat Rev Nephrol 2024; 20(2): 101-19. 
25.  Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 2020; 98(6): 414-22. 
26.  Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal Association. Nephrol Dial Transplant 2023; 38(2): 300-10.
 
Journal of Isfahan Medical School
Volume 44, Issue 876
3rd Week, October
September and October 2026
Pages 1584-1590

  • Receive Date 25 August 2026
  • Accept Date 03 September 2026